AlphaFold solved protein folding.

But that was just the beginning. The AI + biotech intersection is creating an entirely new job market.

What's happening in 2026: AI-designed drugs entering clinical trials. Protein engineering with generative models. Genomic analysis at unprecedented scale. Synthetic biology guided by ML. Personalized medicine based on individual genetic profiles.

The job titles appearing: ML Engineer - Drug Discovery. Computational Biologist with ML expertise. AI Research Scientist - Protein Design. Bioinformatics ML Engineer.

Salaries are extraordinary — $200K-$400K for engineers who understand both ML and biology. The talent pool is tiny because it requires genuine dual expertise.

You don't need a biology PhD. But you need enough biology to understand the problem domain — what a protein structure means, why drug binding matters, how genomic data works.

Companies hiring: Recursion, Insilico Medicine, Isomorphic Labs (Google DeepMind's biotech arm), Absci, Generate Biomedicines, and dozens of funded startups.

The market projection: AI in drug discovery alone is expected to exceed $10B by 2028.

If you're an ML engineer with even a passing interest in biology, invest 3-6 months learning the domain basics. The career opportunities at this intersection are enormous and growing faster than almost any other AI vertical.